Nelson L Michael
Overview
Explore the profile of Nelson L Michael including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
377
Citations
17291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Griffith G, Machmach K, Jian N, Kim D, Costanzo M, Creegan M, et al.
PLoS Pathog
. 2025 Jan;
21(1):e1012916.
PMID: 39888945
New HIV vaccine approaches are focused on eliciting broadly neutralizing antibodies. We characterized early gamma-delta (γδ) T cell responses starting from pre-acquisition and during acute HIV infection (AHI) in participants...
2.
Ehrenberg P, Geretz A, Volcic M, Izumi T, Yum L, Waickman A, et al.
bioRxiv
. 2024 Nov;
PMID: 39605411
Elimination of latent HIV-1 is a major goal of AIDS research but the host factors determining the size of these reservoirs are poorly understood. Here, we investigated whether differences in...
3.
Marichannegowda M, Setua S, Bose M, Sanders-Buell E, King D, Zemil M, et al.
EBioMedicine
. 2024 Oct;
109:105410.
PMID: 39427414
Background: Nearly all transmitted/founder (T/F) HIV-1 are CCR5 (R5)-tropic. While previous evidence suggested that CXCR4 (X4)-tropic HIV-1 are transmissible, virus detection and characterization were not at the earliest stages of...
4.
Macicame I, Bhatt N, Viegas E, Yates A, Nwoga C, Chissumba R, et al.
BMC Public Health
. 2024 Oct;
24(1):2692.
PMID: 39358725
Introduction: Sub-Saharan Africa has a high burden of HIV, particularly among female sex workers (FSW) and men who have sex with men (MSM). Future clinical trials to evaluate vaccines and...
5.
Martinez E, Chang W, Chen W, Hajduczki A, Thomas P, Jensen J, et al.
iScience
. 2024 Oct;
27(10):110624.
PMID: 39351195
The rapid emergence of SARS-CoV-2 variants of concern (VoC) and the threat of future zoonotic sarbecovirus spillover emphasizes the need for broadly protective next-generation vaccines and therapeutics. We utilized SARS-CoV-2...
6.
Nelson G, van Duijn J, Yuki Y, Pau M, Tomaka F, Lavreys L, et al.
J Virol
. 2024 Jul;
98(8):e0028124.
PMID: 39046263
class I variation has the strongest effect genome-wide on outcome after HIV infection, and as such, an understanding of the impact of polymorphism on response to HIV vaccination may inform...
7.
Wieczorek L, Chang D, Sanders-Buell E, Zemil M, Martinez E, Schoen J, et al.
Virol J
. 2024 Jul;
21(1):148.
PMID: 38951814
The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel...
8.
Julg B, Stephenson K, Tomaka F, Walsh S, Tan C, Lavreys L, et al.
NPJ Vaccines
. 2024 May;
9(1):89.
PMID: 38782902
Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We...
9.
Ober Shepherd B, Scott P, Hutter J, Lee C, McCauley M, Guzman I, et al.
Lancet Microbe
. 2024 May;
5(6):e581-e593.
PMID: 38761816
Background: A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown protective efficacy in...
10.
Bakri F, Mukattash H, Esmeiran H, Schluck G, Storme C, Broach E, et al.
Int J Infect Dis
. 2024 May;
145:107079.
PMID: 38697607
Background: Limited epidemiologic studies have been conducted in Jordan describing the HIV epidemic. This study aimed to address this gap to inform HIV prevention and control. Methods: A nationally-representative cross-sectional...